The novel oral anticoagulants

Area of Science:

• Pharmacology
• Hematology
• Clinical Medicine

Background:

• Long-term oral anticoagulation treatment was dominated by warfarin for over 50 years.
• Newer oral anticoagulants have been developed and approved, increasing treatment complexity.
• These agents are used for thrombosis prophylaxis and long-term anticoagulation.

Purpose of the Study:

• To discuss the complexity introduced by new oral anticoagulants in long-term anticoagulation.
• To outline the advantages and limitations of these new agents.
• To highlight the need for clinician understanding and evidence-based management strategies.

Main Methods:

• Review of current literature on oral anticoagulants.
• Pharmacological and clinical comparison of warfarin and new oral agents.
• Analysis of cost-effectiveness and clinical event reduction.

Main Results:

• New oral agents are cost-effective for venous thromboembolism prevention post-orthopedic surgery compared to parenteral options.
• In other settings like atrial fibrillation, they offer convenience at a higher cost with limited improvement over well-managed warfarin.
• The reduction in thrombosis or bleeding events may be marginal for patients on optimal warfarin therapy.

Conclusions:

• Clinicians require a foundational understanding of new oral anticoagulant pharmacology, benefits, and limitations.
• Evidence-based recommendations for managing infrequent scenarios like drug measurement or reversal are needed.
• Further research is necessary to guide clinical practice regarding these novel anticoagulants.